Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 1st Committee on Drugs to Discuss Pediatric Indication for Kyowa Kirin’s Nesp
August 12, 2013
- MHLW Diovan Committee: 3 More Universities Give 1st Probe Updates, SMART Data Rapped “Sloppy”
August 12, 2013
- MHLW Taps 12 Experts to Serve on Diovan Study Committee; J-CLEAR’s Kuwajima, JAMS’s Sone on the List
August 9, 2013
- PMDA to Make Public Adverse Reactions Reported by Patients by Year-End
August 8, 2013
- US FDA Advisory Committee Votes Against Approval of Tolvaptan for Treatment of ADPKD
August 8, 2013
- Education Ministry Set Up Task Force for Prevention of Misconduct in Research, Will Discuss Diovan Issue
August 7, 2013
- Gov’t to Establish “Headquarters to Promote Health and Healthcare Strategy” as HQ for Japanese Version of NIH
August 6, 2013
- First Committee on Drugs Recommends Approval for Long-Acting Injectable Schizophrenia Treatment Xeplion
August 6, 2013
- Health Ministry’s Diovan Study Committee to Start on Aug 9, Minister Expects Attendance of Ex-Novartis Employee
August 5, 2013
- EAD Director to Personally Visit Hospitals to Urge Early Price Agreement
August 5, 2013
- Distribution Reform and Perpetuation of Premium for New Drug Development Are Immediate Top-Priority Issues: EAD Director Jo
August 2, 2013
- CSIMC Subcommittee Discusses Revisions of Drug Pricing Rules; Some Reps Oppose Proposed Rewards for Innovation
August 1, 2013
- “No Surprises” in TPP Negotiations; Gov’t Undecided Whether to Hold Briefing for the Drug Industry: PR Counselor Nakagawa
July 31, 2013
- Combination of Insured and Uninsured Treatments to Be a Top Priority Topic in Discussions by Council for Regulatory Reform
July 30, 2013
- PAFSC’s Second Committee Recommends Approval for Bronchial Asthma Treatment Flutiform, Others
July 29, 2013
- Half of All Drugs, Add’l Indications Approved from FY2009 to FY2012 Underwent Clinical Trials at NHO Hospitals
July 29, 2013
- MHLW-MEXT Joint Committee Agrees to Require Researchers to Store Clinical Research Data for Long Periods
July 26, 2013
- MHLW Might Submit Bill on Online OTC Sales to Extraordinary Diet Session: PFSB Head
July 25, 2013
- CSIMC Approves Questionnaire to Determine Impact of FY2012 Medical Fee Revision on Generic Drug Use
July 25, 2013
- Diovan Study Committee to Hold 1st Meeting in Early August: Minister
July 24, 2013
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…